Pharmalucence formally CIS-US Inc.
Careers News Resources Contact  
    Company
 
  Manufacturing Capabilities
 
  Facility Details 
 
  Nuclear Medicine Products
 
 
 





Company News
Come See Us
Pharmalucence
Company News



March 02, 2011

Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.

Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.

 





For more information, please contact:
John Felock
Director; Sales, Marketing and Customer Service
1-781-687-1245
jfelock@pharmalucence.com



29 Dunham Road, Billerica, MA 01821 | Telephone: 781-275-7120    © Pharmalucence Inc. All rights reserved.
HOME   |   SITE MAP   |   LEGAL STATEMENT   |   PRIVACY POLICY   |